X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-29 | AUPH | Aurinia Pharmaceuticals Inc. | Tang Kevin | CEO, 10% | P - Purchase | $15.29 | +814,606 | 13,044,106 | +7% | +$12,455,227 | |||||
2026-06-01 | GNLX | Genelux Corp | Thomas John | Dir | S - Sale | $2.98 | -10,000 | 472,784 | -2% | -$29,801 | ||||||
| M | 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $4.72 | -652 | 381,509 | 0% | -$3,075 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $95.84 | -30,000 | 381,809 | -7% | -$2,875,103 | |||||
| D | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $100.00 | -3,977 | 0 | -100% | -$397,700 | |||||
| D | 2026-06-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $16.60 | -8,148 | 13,579 | -38% | -$135,253 | |||||
| D | 2026-06-01 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $90.62 | -26,530 | 4,000 | -87% | -$2,404,077 | |||||
| M | 2026-05-29 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $229.20 | -17,537 | 433,459 | -4% | -$4,019,470 | |||||
2026-05-29 | PAHC | Phibro Animal Health Corp | Corcoran E Thomas | Dir | P - Purchase | $31.77 | +10,000 | 41,459 | +32% | +$317,700 | ||||||
| D | 2026-06-01 | NBP | Novabridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $3.94 | -3,494 | 290,154 | -1% | -$13,766 | |||||
| D | 2026-06-01 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale+OE | $227.06 | -5,000 | 41,382 | -11% | -$1,135,316 | |||||
| M | 2026-06-01 | HYPD | Hyperion Defi, Inc. | Jung Hyunsu | See Remarks | P - Purchase | $3.70 | +8,000 | 1,385,676 | +1% | +$29,580 | |||||
2026-06-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $6.06 | -16,667 | 1,176,506 | -1% | -$100,982 | ||||||
| D | 2026-06-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $547.91 | -9,500 | 668,728 | -1% | -$5,205,105 | |||||
| D | 2026-06-01 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $547.87 | -10,000 | 18,876 | -35% | -$5,478,663 | |||||
| A | 2026-05-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $575.97 | -1,500 | 43,153 | -3% | -$863,947 | |||||
2026-05-29 | ANTX | An2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | S - Sale | $4.43 | -265 | 66,583 | 0% | -$1,174 | ||||||
2026-05-29 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Dir | P - Purchase | $2.48 | +150,000 | 13,310,000 | +1% | +$371,610 | ||||||
2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | CFO | S - Sale | $18.99 | -1,177 | 139,252 | -1% | -$22,351 | ||||||
2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale | $18.99 | -6,847 | 484,843 | -1% | -$130,025 | ||||||
2026-06-02 | ASND | Ascendis Pharma A/S | Smith Scott Thomas | EVP, CFO | P - Purchase | $219.00 | +100 | 4,367 | +2% | +$21,900 | ||||||
2026-06-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $69.74 | -12,837 | 2,865,489 | 0% | -$895,252 | ||||||
2026-05-29 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $450.00 | -1,974 | 22,760 | -8% | -$888,300 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.39 | +72,700 | 1,186,221 | +7% | +$100,886 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.34 | +75,000 | 1,532,918 | +5% | +$100,200 | ||||||
2026-06-01 | MAIA | Maia Biotechnology, Inc. | Gryaznov Sergei | Chief Scientific Officer | P - Purchase | $1.35 | +2,000 | 46,511 | +4% | +$2,690 | ||||||
2026-05-29 | KRRO | Korro Bio, Inc. | Aiyar Ram | Pres, CEO | S - Sale | $12.98 | -15,152 | 79,461 | -16% | -$196,673 | ||||||
2026-05-28 | QTTB | Q32 Bio Inc. | Xu Diyong | Dir, 10% | P - Purchase | $8.00 | +1,875,000 | 625,000 | -150% | +$15,000,000 | ||||||
2026-05-28 | QTTB | Q32 Bio Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $8.00 | +1,875,000 | 625,000 | -150% | +$15,000,000 | ||||||
| D | 2026-05-28 | EVMN | Evommune, Inc. | Moss Gregory S. | Chief Business, Legal Officer | S - Sale+OE | $22.83 | -14,223 | 64,010 | -18% | -$324,711 | |||||
| D | 2026-05-28 | EVMN | Evommune, Inc. | Carver Kyle | CFO | S - Sale+OE | $22.84 | -18,175 | 59,335 | -23% | -$415,117 | |||||
2026-06-01 | MDGL | Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | S - Sale | $495.74 | -1,042 | 10,033 | -9% | -$516,561 | ||||||
| D | 2026-06-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $41.67 | -9,000 | 77,389 | -10% | -$375,044 | |||||
2026-06-01 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale | $25.77 | -2,562 | 39,581 | -6% | -$66,024 | ||||||
2026-06-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $23.77 | -4,653 | 105,689 | -4% | -$110,602 | ||||||
2026-06-01 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale | $76.09 | -2,933 | 10,283 | -22% | -$223,172 | ||||||
| D | 2026-06-01 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale+OE | $74.08 | -15,000 | 58,555 | -20% | -$1,111,200 | |||||
2026-06-01 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $74.08 | -5,000 | 15,784 | -24% | -$370,400 | ||||||
| D | 2026-05-29 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $99.64 | -9,000 | 7,825 | -53% | -$896,760 | |||||
2026-06-01 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $13.16 | -4,170 | 149,482 | -3% | -$54,862 | ||||||
2026-05-28 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.95 | -2,860 | 194,655 | -1% | -$39,897 | ||||||
2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | S - Sale | $20.02 | -25,000 | 130,142 | -16% | -$500,543 | ||||||
2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | See remarks below, 10% | S - Sale | $20.02 | -25,000 | 130,142 | -16% | -$500,543 | ||||||
2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.57 | +1,786 | 19,547 | +10% | +$4,590 | ||||||
2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.57 | +2,292 | 10,758 | +27% | +$5,890 | ||||||
2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.57 | +2,129 | 14,258 | +18% | +$5,472 | ||||||
2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.57 | +1,582 | 10,916 | +17% | +$4,066 | ||||||
2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.57 | +1,829 | 10,173 | +22% | +$4,701 | ||||||
| D | 2026-05-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $107.80 | -5,500 | 58,117 | -9% | -$592,923 | |||||
| D | 2026-05-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $553.83 | -9,500 | 668,728 | -1% | -$5,261,365 | |||||
| D | 2026-05-28 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $107.84 | -5,500 | 59,634 | -8% | -$593,101 | |||||
2026-05-28 | PGEN | Precigen, Inc. | Thomasian Harry Jr. | CFO | S - Sale | $4.36 | -41,884 | 554,535 | -7% | -$182,614 | ||||||
2026-05-28 | PGEN | Precigen, Inc. | Tennant Phil | Chief Commercial Officer | S - Sale | $4.36 | -30,272 | 139,369 | -18% | -$131,986 | ||||||
2026-05-28 | PGEN | Precigen, Inc. | Shah Rutul R | COO | S - Sale | $4.36 | -42,703 | 497,751 | -8% | -$186,185 | ||||||
2026-05-28 | PGEN | Precigen, Inc. | Lehr Donald P. | GC | S - Sale | $4.36 | -29,131 | 755,461 | -4% | -$127,011 | ||||||
2026-05-28 | PGEN | Precigen, Inc. | Sabzevari Helen | Pres, CEO | S - Sale | $4.36 | -119,250 | 3,768,872 | -3% | -$519,930 | ||||||
2026-05-29 | ASND | Ascendis Pharma A/S | Bienaime Jean Jacques | Dir | P - Purchase | $223.12 | +500 | 900 | +125% | +$111,562 | ||||||
2026-05-29 | ASND | Ascendis Pharma A/S | Smith Scott Thomas | EVP, CFO | P - Purchase | $223.32 | +250 | 4,267 | +6% | +$55,830 | ||||||
2026-05-28 | JAZZ | Jazz Pharmaceuticals Plc | Patil Neena M | EVP, GC | S - Sale | $236.97 | -1,192 | 52,626 | -2% | -$282,468 | ||||||
| D | 2026-05-28 | JAZZ | Jazz Pharmaceuticals Plc | Pearce Samantha | EVP, Chief Commercial Officer | S - Sale+OE | $235.41 | -6,907 | 50,272 | -12% | -$1,625,977 | |||||
| D | 2026-05-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $16.00 | -679 | 47,122 | -1% | -$10,864 | |||||
2026-05-29 | CMMB | Chemomab Therapeutics Ltd. | Mor George Adi | CEO | P - Purchase | $2.07 | +9,804 | 18,750 | +110% | +$20,246 | ||||||
2026-05-27 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.49 | -101 | 2,671,721 | 0% | -$4,493 | ||||||
2026-05-27 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.49 | -101 | 2,671,721 | 0% | -$4,493 | ||||||
| M | 2026-05-27 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.47 | -141,106 | 622,579 | -18% | -$66,200 | |||||
| D | 2026-05-28 | EQ | Equillium, Inc. | Tom Penny | Principal Accounting Officer | S - Sale+OE | $2.95 | -65,000 | 0 | -100% | -$191,750 | |||||
| DM | 2026-05-27 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $2.79 | -95,833 | 62,586 | -60% | -$267,209 | |||||
2026-05-27 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale | $65.00 | -5,000 | 6,230 | -45% | -$325,000 | ||||||
| D | 2026-05-27 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $65.59 | -75,000 | 118,694 | -39% | -$4,918,944 | |||||
| D | 2026-05-29 | ALKS | Alkermes Plc. | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S - Sale+OE | $42.36 | -16,217 | 7,717 | -68% | -$687,007 | |||||
2026-05-28 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $5.41 | +613,497 | 10,342,134 | +6% | +$3,319,019 | ||||||
| D | 2026-05-28 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $565.63 | -10,000 | 18,876 | -35% | -$5,656,298 | |||||
| D | 2026-05-28 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $565.64 | -9,500 | 668,728 | -1% | -$5,373,592 | |||||
| M | 2026-05-11 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $5.44 | -12,763 | 382,161 | -3% | -$69,451 | |||||
2026-05-28 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO | S - Sale | $31.88 | -120,000 | 833,694 | -13% | -$3,825,717 | ||||||
| D | 2026-05-27 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $26.78 | -33,800 | 229,918 | -13% | -$905,225 | |||||
| M | 2026-05-21 | RNTX | Rein Therapeutics, Inc. | Von Rickenbach Josef H | Dir | P - Purchase | $1.05 | +47,060 | 62,514 | +305% | +$49,561 | |||||
2026-05-27 | PLYX | Polaryx Therapeutics, Inc. | Yang Alex Keun Mo | CEO, 10% | P - Purchase | $4.07 | +88,453 | 24,233,249 | 0% | +$360,004 | ||||||
| D | 2026-05-26 | SEPN | Septerna, Inc. | Shaikhly Samira | Chief People Officer | S - Sale+OE | $30.06 | -11,798 | 793 | -94% | -$354,656 | |||||
2026-05-26 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $53.98 | -64,399 | 50,390 | -56% | -$3,476,116 | ||||||
| D | 2026-05-27 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $575.40 | -9,500 | 668,728 | -1% | -$5,466,283 | |||||
2026-05-27 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $62.18 | -6,428 | 2,225,770 | 0% | -$399,712 | ||||||
2026-05-27 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $77.21 | -7,500 | 396,996 | -2% | -$579,075 | ||||||
2026-05-26 | RIGL | Rigel Pharmaceuticals Inc | Ali-Jackson Kamil | Dir | S - Sale | $29.17 | -2,500 | 12,625 | -17% | -$72,925 | ||||||
2026-05-26 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.05 | -18,572 | 7,249,743 | 0% | -$743,753 | ||||||
2026-05-26 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $18.21 | +2,000 | 20,000 | +11% | +$36,420 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $8.20 | -21,156 | 3,291,981 | -1% | -$173,479 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $8.20 | -2,967 | 266,141 | -1% | -$24,329 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $8.20 | -3,018 | 320,350 | -1% | -$24,748 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $8.20 | -1,858 | 328,795 | -1% | -$15,236 | ||||||
| D | 2026-05-26 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $3.10 | -568 | 0 | -100% | -$1,761 | |||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO, 10% | P - Purchase | $1.41 | +113,879 | 615,790 | +23% | +$160,000 | |||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Garrett Scott T | Dir | P - Purchase | $1.41 | +177,936 | 203,441 | +698% | +$250,000 | |||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Byam Rebecca | CFO | P - Purchase | $1.41 | +14,235 | 57,245 | +33% | +$20,000 | |||||
| M | 2026-05-22 | CNTN | Canton Strategic Holdings, Inc. | Stetz Gary S. | Dir | S - Sale | $3.43 | -100,351 | 134,175 | -43% | -$343,882 | |||||
| DM | 2026-05-22 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | S - Sale+OE | $32.30 | -100,000 | 25,249 | -80% | -$3,229,923 | |||||
| D | 2026-05-22 | OMER | Omeros Corp | Cable Thomas J. | Dir | S - Sale+OE | $11.61 | -7,500 | 35,067 | -18% | -$87,039 | |||||
| D | 2026-05-22 | JAZZ | Jazz Pharmaceuticals Plc | Winningham Rick E | Dir | S - Sale+OE | $241.57 | -2,741 | 9,567 | -22% | -$662,143 | |||||
2026-05-22 | JAZZ | Jazz Pharmaceuticals Plc | McSharry Heather Ann | Dir | S - Sale | $241.00 | -2,000 | 18,449 | -10% | -$482,000 | ||||||
2026-05-26 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale | $21.18 | -5,401 | 24,509 | -18% | -$114,393 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |